Literature DB >> 21617770

New substituted isocoumarins and Dihydroisocoumarins and their cytotoxic activities.

Veronika Hampl1, Isolde Wetzel, Franz Bracher, Jürgen Krauss.   

Abstract

New isocoumarins were prepared in an efficient way from 2-iodobenzoic acid derivatives and hept-1-yne in a Sonogashira reaction, followed by spontaneous cyclization. Catalytic hydrogenation gave the corresponding dihydroisocoumarins. A 4-chloroisocoumarin was prepared on an alternative pathway. Some of the new compounds showed moderate cytotoxic activities against a human leukemia cell line (HL 60).

Entities:  

Keywords:  Cyclization; Cytotoxicity; Dihydroisocoumarins; Isocoumarins; Sonogashira reaction

Year:  2010        PMID: 21617770      PMCID: PMC3097510          DOI: 10.3797/scipharm.1011-10

Source DB:  PubMed          Journal:  Sci Pharm        ISSN: 0036-8709


Introduction

Isocoumarins are a class of natural lactones with high structural diversity exhibiting a broad spectrum of biological activities [1]. Considerable work has been published over decades about their chemistry [2] and biology [3], and a number of natural and synthetic isocoumarins have been shown to exhibit significant cytotoxic and antitumor activities. Among these are numerous isocoumarins bearing various types of substituents (alkyl, alkenyl or aryl groups) at 3-position, as well as the dihydroisocoumarin AI-77-B (A, Figure 1). The latter one was first isolated from Bacillus pumilus, and shows in vitro cytotoxicity against human malignant A375-S2 and cervical cancer HeLa cells [4]. The paraphaeosphaerins (B) from cultures of Paraphaeosphaeria quadriseptana [5] are biogenetically related to the cytotoxic plant metabolites monocillin I and radicicol. NM-3 (C) is a synthetic analogue of cytogenin (E), and potentiates antineoplastic effects of other chemotherapeutic agents and inhibits angiogenesis [6]. This compound is in phase I clinical trials. The isocoumarin 185322 (D), an analogue of NM-3, is an inhibitor of microtubule assembly, and induces mitotic arrest and apoptosis of multiple myeloma cells [7]. Ochratoxin A (F), a mycotoxin from Aspergillus ochraceus shows nephrotoxic, hepatotoxic, carcinogenic and teratogenic properties in animals [8]; recently the European Pharmacopoeia introduced a limit test for ochratoxin A in plant material (Method 2.8.22). Scoparine A (G) was isolated from the North African medical plant Pituranthos scoparius [9].
Fig. 1.

Structures of AI-77-B (A), paraphaeosphaerin A (B), NM-3 (C), 185322 (D), cytogenin (E), ochratoxin A (F), and scoparine A (G).

The biological activities of the abovementioned and other isocoumarins and dihydroisocoumarins [10, 11] make this class of compounds interesting leads for development of new anticancer drugs. In a previous work [12] we prepared a number of isocoumarins and dihydroisocoumarins bearing alkyl and hydroxyalkyl residues at C-3 using a one-pot procedure originally described by Lia and Cheng [13]. Since these products showed only moderate cytotoxic activities, we assumed that additional functional groups at the bicyclic core should be of great importance. An isocoumarin with an isopentyl residue at C-3 was the most cytotoxic one in the previous investigations. This prompted us to investigate the influence of additional lipophilic substituents like halogens (cf. F) and methyl (cf. D) located at various positions of the ring system on the cytotoxicity of 3-alkyl(dihydro)isocoumarins.

Results and Discussion

Chemistry

The isocoumarins 2a–2d were prepared in poor to good yields in one pot reactions starting from commercially available 2-iodobenzoic acid derivatives 1a–d and hept-1-yne involving Sonogashira cross coupling reactions in the presence of zinc chloride [13]. The isocoumarins 2a, 2b [14] and 2d were further hydrogenated under palladium catalysis to give the corresponding dihydroisocoumarins 3a, 3b and 3d (Scheme 1). Hydrogenation of 2c did not appear promising due to the risk of reductive dechlorination.
Sch. 1.

a: Triethylamine, ZnCl2, Pd(PPh3)2Cl2, DMF, 100 °C, 24 h ; b: H2, Pd/C, methanol, 25 °C, 12 h.

The 4-chloroisocoumarin 5 was prepared in a different manner. Methyl 2-iodobenzoate (1e) was reacted in a Sonogashira reaction with hept-1-yne (in the absence of zinc chloride) [15, 16] to give the alkyne 4. Treating 4 with 2 equivalents of CuCl2 and a catalytic amount of N,N-dicyclohexylammonium chloride [17] resulted in cyclization to the chlorinated isocoumarin 5 (Scheme 2).
Sch. 2.

a: Pd(PPh3)2Cl2, CuI, N-ethyl-N,N-dimethylamine, DMF, 25 °C, 12 h; b: CuCl2, N,N-dicyclohexylammonium chloride, 1,2-dichloroethane, 80 °C, 12 h.

Biology

The resulting isocoumarins and dihydroisocoumarins were tested for their cytotoxic activity in a MMT assay using the HL 60 leukemia cell line [18, 19]. The results are shown in Table 1. Since we had found some correlation of the cytotoxic activities with lipophilicity in previous investigations on isocoumarins [12], we also calculated the log P values of the new compounds.
Tab. 1.

Cytotoxicity of the products against HL 60 cell line and calculated partition coefficients log P (calculated with Chem Draw Ultra 10, Cambridge Soft).

CompoundIC50 [μM]log P
2a≥1003.32
2b583.48
2c≥1003.88
2d≥1003.81
3a493.89
3b633.48
3d1034.38
4>10004.28
5≥1004.74
cisplatin5

Discussion

Among the five isocoumarins and three dihydroisocoumarins described here, four compounds, the fluorinated isocoumarin 2b and the dihydroisocoumarins 3a, 3b and 3d, showed measurable, albeit very poor cytotoxic activity. No clear tendency for higher acitivity of one of the two structural subtypes (2 versus 3) can be deduced from these results. Since the log P values of all tested compounds are in the same range, influences of lipophilicity on cytotoxic activity cannot be deduced as well. In conclusion, isocoumarins and dihydroisocoumarins containing exclusively lipophilic residues at both rings show significantly decreased cytotoxic activities compared to established analogues (AI-77-B (A): 0.2 to 0.4 μM against A375-S2 and HeLa cells [4], ochratoxin A (F) and stereoisomers thereof: 0.3 to 5 μM against Hep G2 cells [20]) containing additional polar groups (especially hydroxyl groups) at the benzenoid ring. For obtaining isocoumarins with significant cytotoxicity the presence of polar groups at the ring system seems to be indispensible.

Experimental

Elemental analysis: Heraeus CHN Rapid; IR spectra: Perkin-Elmer FT-IR Paragon 1000; MS (EI, 70 eV): Hewlett Packard MS-Engine; HRMS: Jeol Mstation 700; NMR: Jeol GSX 400 (1H: 400 MHz, 13C: 100 MHz); flash column chromatography (FCC): Kieselgel 60 (230–400 mesh, E. Merck, Darmstadt).

General procedure I: Synthesis of isocoumarins 2a–d

Pd(PPh3)2Cl2 (0.140 g, 0.20 mmol) and ZnCl2 (0.496 g, 4.0 mmol) were added under N2 atmosphere to a solution of aryl iodide (2.0 mmol), hept-1-yne (0.577 g, 6.0 mmol), and triethylamine (10 mmol) in DMF (2 mL). The suspension was heated at 100 °C for 24 h. The components of the suspension were separated by flash column chromatography (n-hexane/ethyl acetate).

General procedure II: Preparation of dihydroisocoumarins 3a,b,d

Pd on charcoal (10%) was added to a solution of the isocoumarin in methanol (20 mL). The suspension was stirred for 12 h under H2 atmosphere at ambient pressure, then the catalyst was filtered off, and the residue was washed with methanol. The combined organic layers were evaporated, and the residue was purified by FCC (n-hexane/ethyl acetate).

3-Pentylisochromen-1-one (2a)

Prepared following General procedure I from 0.496 g (2.0 mmol) 2-iodobenzoic acid to give 310 mg (71 %) as a pale yellow oil. MS (m/z, %): 216 ([M]+·, 34), 160 (36), 118 (100). IR (KBr), ν (cm−1): 2933, 2857, 1716, 1652, 1459, 1176, 769, 705, 592. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.90 (t, J = 7.5 Hz, 3 H, H-5′), 1.35 (m, 4 H, H-3′, H-4′), 1.70 (m, 2 H, H-2′), 2.51 (t, J = 7.5 Hz, 2 H, H-1′), 6.26 (s, 1 H, H-4), 7.34 (d, J = 8.1 Hz, 1 H, H-5), 7.43 (dd, J = J = 8.1 Hz, 1 H, H-7), 7.66 (dd, J = J = 8.1 Hz, 1 H, H-6), 8.24 (d, J = 8.1 Hz, 1 H, H-8). 13C NMR (100 MHz, CDCl3): δ (ppm) 13.92 (C-5′), 22.34 (C-4′), 26.55 (C-2′), 31.13 (C-3′), 33.45 (C-1′), 102.83 (C-4), 120.06 (C-8a), 127.48 (C-7), 129.45 (C-5), 129.46 (C-8), 134.67 (C-6), 137.60 (C-4a), 158.28 (C-3), 163.12 (C-1). HRMS: Calcd. for C14H16O2: 216.1150. Found: 216.1100.

8-Fluoro-3-pentyl-1H-isochromen-1-one (2b) [14]

Prepared following General procedure I from 0.532 g (2.0 mmol) 6-fluoro-2-iodobenzoic acid to give 39 mg (9 %) as a brown oil. MS (m/z, %): 234 ([M]+·, 19), 178 (24), 136 (100), 107 (30). IR (KBr), ν (cm−1): 2956, 2929, 2859, 1731, 1654, 1600, 1562, 1469, 1419, 1378, 1321, 1272, 1240, 1201, 1149, 1087, 1054, 1031, 971, 923, 894, 831, 773, 719, 678, 651, 570, 557. 1H NMR (400 MHz, CDCl3) δ (ppm): 0.91 (t, J = 7.7 Hz, 3 H, H-5′), 1.35 (m, 4 H, H-3′, H-4′), 1.70 (m, 2 H, H-2′), 2.50 (t, J = 7.7 Hz, 2 H, H-1′), 6.23 (d, J = 2.3 Hz, 1 H, H-4), 7.12 (m, 2 H, H-5, H-7), 7.61 (m, 1 H, H-6). HRMS: Calcd. for C14H15O2F: 234.1056. Found: 234.10594. Anal. Calcd. for C14H15O2F: C, 71.78; H, 6.45. Found: C, 72.27; H, 7.66.

6-Chloro-3-pentyl-1H-isochromen-1-one (2c)

Prepared following General procedure I from 0.565 g (2.0 mmol) 4-chloro-2-iodobenzoic acid to give 75 mg (15 %) as a brown oil. MS (m/z, %): 252 ([M]+·, 13), 250 ([M]+·, 35), 194 (45), 152 (100), 123 (20). IR (KBr), ν (cm−1): 2956, 2929, 2859, 1774, 1745, 1660, 1614, 1567, 1475, 1376, 1315, 1253, 1157, 1105, 1012, 831, 808, 777, 728, 688, 669. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.6 Hz, 3 H, H-5′), 1.35 (m, 4 H, H-3′, H-4′), 1.70 (m, 2 H, H-2′), 2.52 (t, J = 7.6 Hz, 2 H, H-1′), 6.18 (s, 1 H, H-4), 7.34 (d, J = 2.0 Hz, 1 H, H-5), 7.39 (dd, J = 8.5 Hz, J = 2.0 Hz, 1 H, H-7), 8.17 (d, J = 8.5 Hz, 1 H, H-8). 13C NMR (100 MHz, CDCl3): δ (ppm) 13.94 (C-5′), 22.35 (C-4′), 26.50 (C-2′), 31.14 (C-3′), 33.55 (C-1′), 102.02 (C-4), 118.41 (C-8a), 124.56 (C-5), 128.02 (C-7), 131.20 (C-8), 139.00 (C-4a), 141.34 (C-6), 159.86 (C-3), 162.30 (C-1). HRMS: Calcd. for C14H15O2Cl: 250.0761. Found: 250.0834. Anal. Calcd. for C14H15O2Cl: C, 67.07; H, 6.03. Found: C: 67.93; H: 6.90.

5-Methyl-3-pentyl-1H-isochromen-1-one (2d)

Prepared following General procedure I from 0.524 g (2.0 mmol) 2-iodo-3-methylbenzoic acid to give 80 mg (18 %) as a yellow oil. MS (m/z, %): 230 ([M]+·, 48), 174 (37), 132 (100), 103 (13). IR (KBr), ν (cm−1): 2927, 2857, 1724, 1652, 1465, 1380, 1270, 1174, 1058, 1022, 759, 705, 584. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.81 (t, J = 7.6 Hz, 3 H, H-5′), 1.29 (m, 4 H, H-3′, H-4′), 1.65 (m, 2 H, H-2′), 2.39 (s, 3 H, Ar-CH3), 2.47 (t, J = 7.6 Hz, 3 H, H-1′), 6.29 (s, 1 H, H-4), 7.26 (dd, J = J = 7.8 Hz, 1 H, H-7), 7.44 (d, J = 7.8 Hz, 1 H, H-6), 8.05 (d, J = 7.8 Hz, 1 H, H-8). 13C NMR (100 MHz, CDCl3): δ (ppm) 13.96 (C-5′), 18.72 (Ar-CH3), 22.45 (C-4′), 26.78 (C-2′), 31.21 (C-3′), 33.86 (C-1′), 99.66 (C-4), 120.12 (C-4a), 127.00 (C-7), 127.36 (C-8), 132.57 (C-8a), 135.90 (C-6), 136.32 (C-5), 157.89 (C-3), 163.52 (C-1). HRMS: Calcd. for C15H18O2: 230.1307. Found: 230.1317. Anal. Calcd. for C15H18O2: C, 77.38; H, 9.74. Found: C: 77.17; H, 8.03.

(±)-3-Pentylisochroman-1-one (rac-(3R)-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3a)

Following General procedure II from 200 mg (0.925 mmol) 3-pentylisochromen-1-one (2a) using 20 mg Pd on charcoal (10 %) to give 160 mg (80 %) as a colourless oil. MS (m/z, %): 218 ([M]+·, 12), 147 (72), 118 (100), 105 (28). IR (KBr), ν (cm−1): 2943, 2855, 1705, 1650, 1455, 1170, 765, 701, 593. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.2 Hz, 3 H, H-5′), 1.34 (m, 4 H, H-3′, H-4′), 1.47 (m, 1 H, H-2′), 1.58 (m, 1 H, H-2′), 1.72 (m, 1 H, H-1′), 1.88 (m, 1 H, H-1′), 2.94 (m, 2 H, H-4), 4.52 (m, 1 H, H-3), 7.24 (dd, J = J = 7.6 Hz, 1 H, H-5), 7.38 (dd, J = J = 7.6 Hz, 1 H, H-6), 7.52 (ddd, J = J = 7.6 Hz, J 1.4 Hz, 1 H, H-7), 8.09 (d, J = 7.6 Hz, 1 H, H-8). 13C NMR (100 MHz, CDCl3): δ (ppm) 14.01 (C-5′), 22.53 (C-4′), 24.60 (C-2′), 31.57 (C-3′), 33.21 (C-4), 34.94 (C-1′), 77.39 (C-3), 125.23 (C-4a), 127.37 (C-5), 127.58 (C-6), 130.23 (C-8), 133.64 (C-7) 139.25 (C-8a), 165.74 (C-1). HRMS: Calcd. for C14H18O2: 218.1307. Found: 218.1286. Anal. Calcd. for C14H18O2: C, 77.38; H, 9.74. Found: C, 77.17; H, 8.03.

(±)-8-Fluoro-3-pentylisochroman-1-one (rac-(3R)-8-fluoro-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3b)

Following General procedure II from 28 mg (0.12 mmol) 8-fluoro-3-pentylisochromen-1-one (2b) using 5 mg Pd on charcoal (10 %) to give 25 mg (89 %) as a pale yellow oil. IR (KBr), ν (cm−1): 3456, 2955, 2928, 2858, 1731, 1660, 1615, 1582, 1470, 1378, 1358, 1253, 1099, 1057, 1031, 803, 780, 727, 690. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.1 Hz, 3 H, H-5′), 1.33 (m, 4 H, H-3′, H-4′), 1.45 (m, 1 H, H-2′), 1.57 (m, 1 H, H-2′), 1.71 (m, 1 H, H-1′), 1.87 (m, 1 H, H-1′), 2.94 (m, 2 H, H-4), 4.48 (m, 1 H, H-3), 7.09 (m, 2 H, H-5 and H-7), 7.50 (m, 1 H, H-6). 13C-NMR (125 MHz, CDCl3) δ (ppm): 14.04 (C-5′), 22.53 (C-4′), 24.55 (C-2′), 31.58 (C-4), 33.65 (d, J = 2.4 Hz, C-4), 34.73 (C-1′), 78.53 (C-3), 113.87 (d, J = 6.9 Hz, C-8a), 116.01 (d, J = 21.6 Hz, C-7), 123.07 (d, J = 3.8 Hz, C-5), 134.95 (d, J = 10.0 Hz, C-6), 141.90 (C-4a), 161.43 (C-1), 162.99 (d, J = 264.8 Hz, C-8). HRMS: Calcd. for C15H20O2: 236.1213. Found: 236.1195.

(±)-5-Methyl-3-pentyl-isochroman-1-one (rac-(3R)-5-methyl-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3d)

Following General procedure II from 40 mg (0.17 mmol) 5-methyl-3-pentylisochromen-1-one (2d) using 4 mg Pd on charcoal (10 %) to give 35 mg (89 %) as a colourless oil. MS (m/z, %): 232 ([M]+·, 21), 161 (63), 133 (100), 105 (29). IR (KBr), ν (cm−1): 2956, 2929, 2859, 1774, 1745, 1660, 1614, 1567, 1475, 1376, 1315, 1253, 1157, 1105, 1012, 831, 808, 777, 728, 688, 669. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.0 Hz, 3 H, H-5′), 1.34 (m, 4 H, H-3′, H-4′), 1.49 (m, 1 H, H-2′), 1.59 (m, 1 H, H-2′), 1.74 (m, 1 H, H-1′), 1.89 (m, 1 H, H-1′), 2.32 (s, 3 H, Ar-CH3), 2.77 (dd, J = 3.3 Hz, J = 16.6 Hz, 1 H, H-4), 2.92 (dd, J = 3.3 Hz, J = 16.6 Hz, 1 H, H-4), 4.48 (m, 1 H, H-3), 7.27 (dd, J = J = 7.7 Hz, 1 H, H-7), 7.39 (d, J = 7.7 Hz, 1 H, H-6), 7.96 (d, J = 7.7 Hz, 1 H, H-8). 13C-NMR (125 MHz, CDCl3) δ (ppm): 13.98 (C-5′), 18.85 (Ar-CH3), 22.49 (C-4′), 24.62 (C-2′), 30.23 (C-4), 31.57 (C-3′), 35.08 (C-1′), 77.25 (C-3), 125.20 (C-4a), 126.93 (C-7), 128.07 (C-8), 134.94 (C-6), 135.00 (C-8a), 137.78 (C-5), 166.08 (C-1). HRMS: Calcd. for C15H20O2: 232.14633. Found: 232.14310.

Methyl 2-(hept-1-yn-1-yl)benzoate (4)

2.62 g (10.0 mmol) methyl 2-iodobenzoate, 0.96 g (10.0 mmol) hept-1-yne, 200 mg (2.4 mmol) CuI and 400 mg (0.6 mmol) PdCl2(PPh3)2 were dissolved in 20 mL N-ethyl-N,N-dimethylamine and the solution was stirred for 12 h at room temperature. The solvent was evaporated and the residue was quenched with 20 mL 5% aqueous Na2SO3-solution. The mixture was extracted with diethyl ether (3 x 25 mL) and the combined organic layers were dried over Na2SO4. The solvent was evaporated and the residue was purified by FCC (isohexane/ethyl acetate 5:1) to give 740 mg (32 %) of 4 as a pale brown oil. MS (m/z, %): 230 ([M]+·, 22), 215 (36), 174 (100), 159 (72), 133 (96), 115 (42). IR (KBr), ν (cm−1): 3066, 2954, 2931, 2859, 2235, 1733, 1596, 1565, 1484, 1446, 1432, 1294, 1274, 1249, 1130, 1083, 962, 881, 757, 701, 538. 1H-NMR (400 MHz, CDCl3) δ (ppm): 0.90 (t, J = 7.2 Hz, 3 H, H-7′), 1.35 (m, 2 H, H-5′), 1.43 (m, 2 H, H-6′), 1.62 (m, 2 H, H-4′), 2.44 (t, J = 7.2 Hz, 2 H, H-3′), 3.88 (s, 3 H, OCH3), 7.27 (ddd, J = 7.8 Hz, J = 1.2 Hz, 1 H, H-4), 7.38 (ddd, J = 7.8 Hz, J = 1.2 Hz, 1 H, H-5), 7.48 (dd, J = 7.8 Hz, J = 1.2 Hz, 1 H, H-3), 7.85 (dd, J = 7.8 Hz, J = 1.2 Hz, 1 H, H-6). 13C NMR (100 MHz, CDCl3): δ (ppm) 13.91 (C-7′), 19.66 (C-6′), 22.16 (C-4′), 28.31 (C-5′), 31.03 (C-3′) 51.93 (OCH3), 79.10 (C-1′), 95.95 (C-2′), 124.50 (C-2), 127.00 (C-4), 130.03 (C-5), 131.36 (C-3), 131.38 (C-1), 134.10 (C-6), 166.91 (C=O). Anal. Calcd. for C15H18O2: C, 78.26; H, 7.83. Found: C, 78.69; H, 7.76.

4-Chloro-3-pentyl-1H-isochromen-1-one (5)

0.690 g (3.20 mmol) methyl 2-(hept-1-ynyl)-benzoate (4), 0.081 g (6.2 mmol) CuCl2, 0.065 g (0.30 mmol) N,N-dicyclohexylammonium chloride and 30 mL 1,2-dichloroethane were dissolved under N2 atmosphere and heated at 80 °C with stirring. After 12 h the solvent was evaporated and the residue was purified by FCC (isohexane/ethyl acetate 10:1) to give 580 mg (73 %) of 5 as a pale brown oil. MS (m/z, %): 252 ([M]+·, 31), 250 ([M]+·, 100), 215 (18), 194 (69), 165 (26), 159 (51), 152 (43). IR (KBr), ν (cm−1): 3072, 3035, 2956, 2931, 2859, 1745, 1631, 1602, 1567, 1479, 1465, 1319, 1288, 1052, 1031, 975, 964, 925. 1H NMR (400 MHz, CDCl3): δ (ppm) 0.90 (t, J = 7.7 Hz, 3 H, H-5′), 1.37 (m, 4 H, H-3′, H-4′), 1.73 (m, 2 H, H-2′), 2.75 (t, J = 7.7 Hz, 2 H, H-1′), 7.53 (ddd, J = 7.8 Hz, J = 1.2 Hz, 1 H, H-7), 7.79 (m, 2 H, H-5, H-6), 8.26 (d, J = 7.8 Hz, 1 H, H-8). 13C NMR (100 MHz, CDCl3): δ (ppm) 13.89 (C-5′), 22.30 (C-4′), 26.41 (C-2′), 31.17 (C-1′, 3′), 110.89 (C-4), 120.13 (C-8a), 123.14 (C-5), 128.35 (C-7), 129.73 (C-8), 135.17 (C-6), 135.54 (C-4a), 154.66 (C-3), 161.31 (C-1). Anal. Calcd. for C14H15O2Cl: C, 67.07; H, 6.03. Found: C, 67.24; H, 6.45.

MTT assay

A solution of the substance in dimethyl sulfoxide (1 μl, concentrations in the range from 10−9 to 10−4 mol/l) was incubated with 99 μl of a suspension of HL 60 cells (9 × 105 cells/ml) in RPMI 1640 medium (PAA Laboratories) with 10% FKS in 96 well plates for 24 h. Then, 10 μl of a solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in PBS (5 mg/ml) were added and the plate was incubated for another 2 h. The cells were quenched with 190 μl dimethyl sulfoxide and after a few min, the plates were evaluated on a Dynatech MRX at a wavelength of 570 nm; the reference wavelength was 630 nm [18]. The experiments were performed in triplicate.
  11 in total

1.  Total synthesis and cytotoxicity evaluation of all ochratoxin A stereoisomers.

Authors:  Benedikt Cramer; Henning Harrer; Kazuhiko Nakamura; Daisuke Uemura; Hans-Ulrich Humpf
Journal:  Bioorg Med Chem       Date:  2009-10-30       Impact factor: 3.641

2.  Sg17-1-4, a novel isocoumarin from a marine fungus Alternaria tenuis Sg17-1.

Authors:  Yong-Fu Huang; Lin-Hao Li; Li Tian; Li Qiao; Hui-Ming Hua; Yue-Hu Pei
Journal:  J Antibiot (Tokyo)       Date:  2006-06       Impact factor: 2.649

3.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.

Authors:  S J Collins; R C Gallo; R E Gallagher
Journal:  Nature       Date:  1977-11-24       Impact factor: 49.962

4.  A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells.

Authors:  Takeshi Kawano; Naoki Agata; Surender Kharbanda; David Avigan; Donald Kufe
Journal:  Cancer Chemother Pharmacol       Date:  2006-07-08       Impact factor: 3.333

5.  Synthesis of isocoumarins and alpha-pyrones via tandem Stille reaction/heterocyclization.

Authors:  Khalil Cherry; Jean-Luc Parrain; Jérôme Thibonnet; Alain Duchêne; Mohamed Abarbri
Journal:  J Org Chem       Date:  2005-08-19       Impact factor: 4.354

6.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

7.  Short and efficient approach towards macrocyclic lactones based on a Sonogashira reaction.

Authors:  Jürgen Krauss; Doris Unterreitmeier; Christine Neudert; Franz Bracher
Journal:  Arch Pharm (Weinheim)       Date:  2005-12       Impact factor: 3.751

8.  Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.

Authors:  Corinne L Reimer; Naoki Agata; Jennifer G Tammam; Michael Bamberg; William M Dickerson; George D Kamphaus; Susan L Rook; Michael Milhollen; Robert Fram; Raghu Kalluri; Donald Kufe; Surender Kharbanda
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

9.  Alkylated isocoumarins from Pituranthos scoparius.

Authors:  Haba Hamada; Benkhaled Mohammed; Georges Massiot; Christophe Long; Catherine Lavaud
Journal:  Nat Prod Res       Date:  2004-10       Impact factor: 2.861

10.  Bioactive isocoumarins isolated from the endophytic fungus Microdochium bolleyi.

Authors:  Wen Zhang; Karsten Krohn; Siegfried Draeger; Barbara Schulz
Journal:  J Nat Prod       Date:  2008-05-30       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.